Last reviewed · How we verify
Pfizer BNT162b2 COVID-19 vaccine — Competitive Intelligence Brief
marketed
Biologic
Live · refreshed every 30 min
Target snapshot
Pfizer BNT162b2 COVID-19 vaccine (Pfizer BNT162b2 COVID-19 vaccine) — National Institute of Allergy and Infectious Diseases (NIAID).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pfizer BNT162b2 COVID-19 vaccine TARGET | Pfizer BNT162b2 COVID-19 vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pfizer BNT162b2 COVID-19 vaccine CI watch — RSS
- Pfizer BNT162b2 COVID-19 vaccine CI watch — Atom
- Pfizer BNT162b2 COVID-19 vaccine CI watch — JSON
- Pfizer BNT162b2 COVID-19 vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Pfizer BNT162b2 COVID-19 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/pfizer-bnt162b2-covid-19-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab